A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Required: KRAS mutation

Documentation of mutated KRAS gene; Confirmed KRAS mutation, any variant

Required: KRAS mutation (any variant except previously treated G12C)

NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C

Must have received: systemic therapy — metastatic pancreatic adenocarcinoma

PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy.

Must have received: platinum-based chemotherapy — NSCLC

NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen and checkpoint inhibitor therapy

Must have received: checkpoint inhibitor — NSCLC

NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen and checkpoint inhibitor therapy

Must have received: EGFR tyrosine kinase inhibitor — NSCLC with EGFR, ALK, or other genomic tumor alterations

for participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations

Must have received: systemic therapy — metastatic colorectal carcinoma

CRC (2-3L): Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, or irinotecan; for one prior treatment, exposure to VEGF/VEGF receptor (VEGFR) inhibitor is optional

Must have received: systemic therapy — other tumors

Other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy.

Cannot have received: chemotherapy

Exception: neoadjuvant/adjuvant therapy allowed if relapse did not occur within 6 months of completing adjuvant treatment

PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy for metastatic disease. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of completing these forms of adjuvant treatment.

Cannot have received: chemotherapy

Exception: adjuvant chemotherapy or adjuvant chemo-radiotherapy allowed if relapse did not occur within 6 months of completion of adjuvant therapy

CRC (1L) Cohort B3: Participants must not have had prior chemotherapy for advanced or metastatic disease. Participant could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy, as long as relapse did not occur within 6 months of complete of adjuvant therapy.

Cannot have received: systemic therapy

NSCLC (1L) Cohort C2: Participants must not have received prior systemic treatment setting. NSCLC (1L) Cohort C3: Participants with any TPS and must not have received prior systemic treatment setting.